scholarly journals The Effect of Egg Consumption in Hyperlipidemic Subjects during Treatment with Lipid-Lowering Drugs

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Theerawut Klangjareonchai ◽  
Supanee Putadechakum ◽  
Piyamitr Sritara ◽  
Chulaporn Roongpisuthipong
Keyword(s):  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Lipid Profiles ◽  
Lipid Lowering ◽  
Cholesterol Ratio ◽  
Regular Diet ◽  
Egg Consumption ◽  
Lipid Lowering Drugs ◽  
Reduce Risk ◽  
Body Compositions

Background. Limiting egg consumption to avoid high cholesterolemia is recommended to reduce risk of cardiovascular disease. However, recent evidences suggest that cholesterol from diet has limited influence on serum cholesterol.Objective. To assess the effect of egg consumption on lipid profiles in hyperlipidemic adults treated with lipid-lowering drugs.Material and Method. Sixty hyperlipidemic subjects, mean age of 61 years, who had been treated with lipid-lowering drugs. Every subject was assigned to consume additional 3 eggs per day with their regular diet for 12 weeks. Measurements for lipid profiles and body compositions were performed.Results. An additional consumption of 3 eggs per day for 12 weeks increased HDL-cholesterol by2.46±6.81 mg/dL (P<0.01) and decreased LDL-cholesterol to HDL-cholesterol ratio by0.13±0.46(P<0.05). No significant changes were found in other lipid profiles. Body weight and body mass index were significantly increased at 12th week by0.52±1.83 kg and0.31±0.99 kg/m2, respectively (P<0.05).Conclusion. In hyperlipidemic adults who were treated with lipid-lowering drugs, the consumption of additional 3 eggs per day to their regular diet will increase the level of HDL-cholesterol and decrease the ratio of LDL-cholesterol to HDL-cholesterol.

scholarly journals Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction?

2011 ◽  
Vol 139 (1-2) ◽  
pp. 30-36
Author(s):  
Emina Aleksic ◽  
Radmila Stamenkovic ◽  
Mirjana Lapcevic ◽  
Marina Deljanin-Ilic ◽  
Dragan Djordjevic ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Ldl Cholesterol ◽  
Plasma Concentrations ◽  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Diabetic Patients ◽  
Prevention Measures ◽  
Previous Myocardial Infarction ◽  
Lipid Lowering Drugs ◽  
Coronary Events

Introduction. Considering that dyslipidaemia is an important factor for cardiovascular diseases, target lipid levels are rarely reached in everyday clinical practice. Objective. The objective of this study was to evaluate how often we achieve the treatment goals for the lipid parameters in the diabetic and non-diabetic patients after the previous myocardial infarction (MI). Methods. The survey included 118 patients (84 males and 34 females), mean age 59.38?9.86 years, 34 (28.8%) of them diabetics, with the history of MI in the previous 3 years. The patients were selected from the database of multicentre prospective interventional study ?Secondary prevention of coronary heart disease and cerebrovascular diseases?, conducted in 2005 on 1,189 patients in Serbia. The patients were further followed in the period from 18 (5th visit) and 36 months (6th visit) after inclusion into the study from 2005-2008. Their lipid status, the use of lipid-lowering drugs, and the independent prognostic factors for major adverse coronary events were identified. In the beginning of the study, all patients were informed about the importance of lifestyle change and active approach to treatment. The accomplishment of secondary preventive measures was estimated on the basis of the European guidelines on secondary prevention of the coronary heart disease. Results. Three years after introduction of the preventive measures, diabetics had a higher prevalence of the target levels of the total cholesterol (21.2% vs. 7.6%) and HDL-cholesterol than non-diabetics (100% vs. 87.3%) (p<0.05). Non-diabetics had significantly higher prevalence of the target levels of LDL-cholesterol than diabetics (19% vs. 3%) (p<0.05). No significant differences were found in the prevalence of the treatment goals of triglycerides in diabetic (42.4%) and non-diabetic patients (60.8%) (p>0.05). At the end of the study, after applying secondary prevention measures, 27.3% of diabetics did not use lipid-lowering drugs. The percentage of non-diabetics using no lipid-lowering drugs was lower (20.3%), but the difference was not statistically significant (p>0.05). By using the method Enter Cox regression multivariant analysis, the change in the level of triglycerides, total and LDL-cholesterol were singled out as independent prognostic factors for major adverse coronary events. Conclusion. Our study has shown high prevalence of increased plasma concentrations in the total, LDL-cholesterol and triglycerides and low plasma concentrations of HDL-cholesterol, as well as the insufficient use of lipid-lowering drugs in diabetic and non-diabetic patients with previous MI. Decreasing the total cholesterol and increasing the HDL-cholesterol are significant, decreasing of triglycerides and LDL-cholesterol does not suffice. Therefore, secondary prevention measures of cardiovascular events should be intensified, especially in patients with diabetes.

scholarly journals Are current dietary guidelines relevant to subjects on cholesterol-lowering drugs?

2019 ◽  
Vol 79 (1) ◽  
pp. 88-94 ◽  
Author(s):  
Andrew M. Salter
Keyword(s):  
Risk Factors ◽  
Ldl Cholesterol ◽  
Dietary Habits ◽  
Hdl Cholesterol ◽  
Premature Mortality ◽  
Dietary Guidelines ◽  
Lipid Lowering ◽  
Dietary Advice ◽  
Processed Meat ◽  
Lipid Lowering Drugs

The present paper reviews the evidence as to whether patients on lipid-lowering drugs should restrict dietary SFA intake. Premature mortality from atherosclerotic CVD has fallen dramatically in many high-income countries. This appears to be due to a combination of improved treatment following a cardiovascular event and reduced risk factors, including LDL-cholesterol. Whether this reduction is due to changes in dietary habits, or the increasing availability of highly potent cholesterol-reducing drugs remains to be firmly established. While reducing dietary SFA intake has been the cornerstone of public health nutrition policy for several decades, the efficacy of such dietary changes has been challenged in recent years. While there remains a lack of consensus in the literature, there is an emerging view that dietary advice should be specifically modified to emphasise replacing SFA with PUFA in the diet rather than carbohydrate. The advice to moderate dietary SFA intake given to the general population is usually also given to those individuals at high risk of CVD who are prescribed lipid-lowering drugs. There is limited evidence to suggest that any potential benefit of such a diet on LDL-cholesterol may be offset by a concurrent decrease in HDL-cholesterol. However, as diets rich in SFA are frequently energy-dense, and rich in red and processed meat (potential risk factors for CVD in themselves), it would seem prudent to continue to advise patients on lipid-lowering drugs to maintain a low-fat diet.

scholarly journals Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints—A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

2016 ◽  
Vol 62 (7) ◽  
pp. 930-946 ◽  
Author(s):  
Børge G Nordestgaard ◽  
Anne Langsted ◽  
Samia Mora ◽  
Genovefa Kolovou ◽  
Hannsjörg Baum ◽  
...  
Keyword(s):  
Total Cholesterol ◽  
Familial Hypercholesterolemia ◽  
Apolipoprotein B ◽  
Ldl Cholesterol ◽  
Clinical Chemistry ◽  
Hdl Cholesterol ◽  
Lipid Profiles ◽  
Apolipoprotein A1 ◽  
Lipoprotein A ◽  
Remnant Cholesterol

Abstract AIMS To critically evaluate the clinical implications of the use of non-fasting rather than fasting lipid profiles and to provide guidance for the laboratory reporting of abnormal non-fasting or fasting lipid profiles. METHODS AND RESULTS Extensive observational data, in which random non-fasting lipid profiles have been compared with those determined under fasting conditions, indicate that the maximal mean changes at 1–6 h after habitual meals are not clinically significant [+0.3 mmol/L (26 mg/dL) for triglycerides; −0.2 mmol/L (8 mg/dL) for total cholesterol; −0.2 mmol/L (8 mg/dL) for LDL cholesterol; +0.2 mmol/L (8 mg/dL) for calculated remnant cholesterol; −0.2 mmol/L (8 mg/dL) for calculated non-HDL cholesterol]; concentrations of HDL cholesterol, apolipoprotein A1, apolipoprotein B, and lipoprotein(a) are not affected by fasting/non-fasting status. In addition, non-fasting and fasting concentrations vary similarly over time and are comparable in the prediction of cardiovascular disease. To improve patient compliance with lipid testing, we therefore recommend the routine use of non-fasting lipid profiles, whereas fasting sampling may be considered when non-fasting triglycerides are &gt;5 mmol/L (440 mg/dL). For non-fasting samples, laboratory reports should flag abnormal concentrations as triglycerides ≥2 mmol/L (175 mg/dL), total cholesterol ≥5 mmol/L (190 mg/dL), LDL cholesterol ≥3 mmol/L (115 mg/dL), calculated remnant cholesterol ≥0.9 mmol/L (35 mg/dL), calculated non-HDL cholesterol ≥3.9 mmol/L (150 mg/dL), HDL cholesterol ≤1 mmol/L (40 mg/dL), apolipoprotein A1 ≤1.25 g/L (125 mg/dL), apolipoprotein B ≥1.0 g/L (100 mg/dL), and lipoprotein(a) ≥50 mg/dL (80th percentile); for fasting samples, abnormal concentrations correspond to triglycerides ≥1.7 mmol/L (150 mg/dL). Life-threatening concentrations require separate referral for the risk of pancreatitis when triglycerides are &gt;10 mmol/L (880 mg/dL), for homozygous familial hypercholesterolemia when LDL cholesterol is &gt;13 mmol/L (500 mg/dL), for heterozygous familial hypercholesterolemia when LDL cholesterol is &gt;5 mmol/L (190 mg/dL), and for very high cardiovascular risk when lipoprotein(a) &gt;150 mg/dL (99th percentile). CONCLUSIONS We recommend that non-fasting blood samples be routinely used for the assessment of plasma lipid profiles. Laboratory reports should flag abnormal values on the basis of desirable concentration cutpoints. Non-fasting and fasting measurements should be complementary but not mutually exclusive.

Complex lipid-lowering treatment options in patients with a history of acute coronary syndrome

2011 ◽  
Vol 152 (8) ◽  
pp. 296-302 ◽  
Author(s):  
Győző Dani ◽  
László Márk ◽  
András Katona
Keyword(s):  
Acute Coronary Syndrome ◽  
Serum Lipid ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Coronary Syndrome ◽  
Target Values ◽  
History Of ◽  
Lipid Parameters

Authors aimed to assess how target values in serum lipid concentrations (LDL- and HDL-cholesterol, triglyceride) can be achieved in patients with a history of acute coronary syndrome during follow up in an outpatient cardiology clinic. Methods: 201 patients with a history of acute coronary syndrome were included and were followed up between January 1 and May 31, 2007.Authors analyzed serum lipid parameters of the patients and the lipid-lowering medications at the time of the first meeting and during follow up lasting two years. Results: During the enrollment visit only 26.4% of the patients had serum LDL cholesterol at target level, whereas high triglycerides and low HDL cholesterol levels were observed in 40.3% and 33.3% of the patients, respectively. Only 22 patients (10.9%) achieved the target levels in all three lipid parameters. Of the 201 patients, 179 patients participated in the follow up, and data obtained from these patients were analyzed. There was a positive trend toward better lipid parameters; 42.5% of the patients reached the desired LDL-cholesterol target value and 17.3% of the patients had HDL-cholesterol and triglycerides target values. Conclusions: These findings are consistent with those published in the literature. Beside the currently used therapeutic options for achieving optimal LDL-cholesterol, efforts should be made to reduce the so-called “residual cardiovascular risk” with the use of a widespread application of combination therapy. Orv. Hetil., 2011, 152, 296–302.

scholarly journals Serum LDL Cholesterol/HDL Cholesterol Ratio Alternative to Albumin in Relation to Coronary Heart Disease

1970 ◽  
Vol 7 (2) ◽  
pp. 51-53
Author(s):  
S Parveen ◽  
Md Shamsuzzaman ◽  
Khursid Ara Begum ◽  
Nizamul Haque Bhuiyan ◽  
R Yeasmin ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Excellent Correlation ◽  
Albumin Ratio ◽  
Cholesterol Ratio ◽  
Better Than

In a study of coronary heart disease in males, their is a correlation between LDL cholesterol/ HDL cholesterol ratio & albumin(r= 0.46,p < 0.001).We then correlated the LDL cholesterol: albumin ratio( TC: Alb) with the LDL c : HDL -c ratio ( r= 0.12,p < 0.001).An excellent correlation was obtained between LDL-C : Alb ratio separated the patients with normal ( < 5) and increased (>5) LDL-C: HDL-C ratio better than LDL-C by itself(Amin A Nanji, Suseela Reddy et al).    DOI = 10.3329/jom.v7i2.1364 J MEDICINE 2006; 7 : 51-53

scholarly journals Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation

2004 ◽  
Vol 91 (3) ◽  
pp. 393-401 ◽  
Author(s):  
Pekka Puska ◽  
Vesa Korpelainen ◽  
Lars H. Høie ◽  
Eva Skovlund ◽  
Knut T. Smerud
Keyword(s):  
Ldl Cholesterol ◽  
Intervention Group ◽  
Gastrointestinal Symptoms ◽  
Hdl Cholesterol ◽  
Dropout Rate ◽  
Soya Protein ◽  
Lipid Lowering ◽  
Control Group ◽  
Lowering Effect ◽  
Lipid Lowering Effect

The objective was to study whether a yoghurt containing isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids is more effective in lowering total and LDL-cholesterol than a placebo. One hundred and forty-three subjects were randomised to the soya group (n69) or to the placebo (n74). The mean baseline levels were 7·6 and 5·1mmol/l for total and LDL-cholesterol, respectively. Fasting serum lipoproteins were assessed five times during the 8-week intervention period, and 4 weeks thereafter. The results were analysed by a mixed model for unbalanced repeated measurements. During the intervention, there were highly significant differences in lipid-lowering effect in favour of the active soya intervention group compared with the control group. The significant differences were for total cholesterol (estimated mean difference 0·40mmol/l;P<0·001), LDL-cholesterol (0·39mmol/l;P<0·001), non-HDL-cholesterol (0·40mmol/l;P<0·001) and for the total:HDL-cholesterol ratio (0·23;P=0·005). There was no difference in the effects on HDL-cholesterol, triacylglycerols or homocysteine. The lipid-lowering effect occurred within 1–2 weeks of intervention, and was not due to weight loss. The safety profile for active soya was similar to the placebo group, except for gastrointestinal symptoms, which caused a significantly higher dropout rate (fourteenv. three subjects) among the subjects taking active soya.

scholarly journals Lipid profiles in smoking and non-smoking male adolescents

2014 ◽  
Vol 54 (4) ◽  
pp. 232
Author(s):  
Sigit Prastyanto ◽  
Mei Neni Sitaresmi ◽  
Madarina Julia
Keyword(s):  
Total Cholesterol ◽  
Tobacco Smoking ◽  
Ldl Cholesterol ◽  
Smoking Status ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Lipid Profiles ◽  
Cross Sectional ◽  
Mean Differences

Background The prevalence of smoking in adolescentstends to increase. Smoking is associated with a higher risk ofdyslipidemia.Objective To compare the lipid profiles of tobacco-smoking andnon-tobacco-smoking male adolescents.Methods We performed a cross- sectional study in three vocationalhigh schools in Yogyakarta from January to April 2011. Dataon smoking status, duration of smoking and number cigarettesconsumed per day were collected by questionnaires. We randomlyselected 50 male smokers and 50 male non-smokers as the studysubjects.Results Mean differences between smokers and non-smokerswere 44.5 (95%CI 28. 7 to 60.1) mg/dL for triglyceride levels; 8.0(95% CI 1.0 to 14.9) mg/dL for low density lipoprotein (LDL)cholesterol; 11.8 (1.1 to 22.4) mg/dL for total cholesterol and -5.7mg/dL (95% CI -8.8 to -2.6) for high density lipoprotein (HDL)cholesterol. Mean differences (95% CI) between smokers whohad engaged in smoking for > 2 years and those who had smokedfor :S:2 years were -18.1 (95% CI -33 .9 to -2.3) mg/dL for totalcholesterol; -49.4 (95% CI -67.2 to -3 1.5) mg/dL for triglycerides.Mean differences between those who smoked > 5 cigarettes/dayand :s:5 cigarettes per day were -18 .4 (95% CI -32.8 to -4.1) mg/dL for total cholesterol and -29.1 (95% CI -53.6 to -4.6) mg/dLfor triglycerides.Conclusion Smoking more than 5 cigarettes/day significantlyincreases total cholesterol, LDL cholesterol, and triglyceridelevels, as well as reduces HDL cholesterol levels; while smokingmore than 2 years significantly increases total cholesterol andtriglyceride levels

Sign in / Sign up

Export Citation Format

Share Document